Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition

Clinical and Experimental Immunology

Volumn 155, Issue 3, 2009, Pages 504-513

  Ames, E ^a   Hallett, W H D ^a   Murphy, W J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Natural killer cell; Proteasome inhibition

Indexed keywords

BORTEZOMIB; DEATH RECEPTOR; MESSENGER RNA; PROTEASOME; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL KILLING; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SENSITIZATION; SURVIVAL; THERAPY EFFECT; TUMOR GROWTH; UPREGULATION;

ANIMALS; APOPTOSIS; BORONIC ACIDS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MICE; MICE, SCID; PROTEASE INHIBITORS; PYRAZINES; RECEPTORS, DEATH DOMAIN; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59249101291     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03818.x     Document Type: Article

References (32)

1. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002 8 (Suppl. 4 S49 54.
2. Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 2003 17 : 790 9.
3. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006 46 : 189 213.
4. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006 57 : 33 47.
5. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002 82 : 373 428.
6. Asher G, Reuven N, Shaul Y. 20S proteasomes and protein degradation 'by default'. Bioessays 2006 28 : 844 9.
7. Kane RC, Dagher R, Farrell A et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007 13 : 5291 4.
8. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007 12 : 664 89.
9. Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007 13 : 1208 15.
10. Lara PN Jr., Koczywas M, Quinn DI et al. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a Phase I California Cancer Consortium trial. J Thorac Oncol 2006 1 : 126 34.
11. Ryan DP, O'Neil BH, Supko JG et al. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006 107 : 2688 97.
12. Sayers TJ, Brooks AD, Koh CY et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003 102 : 303 10.
13. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007 26 : 3745 57.
14. Hallett WH, Ames E, Motarjemi M et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008 180 : 163 70.
15. Herberman RB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. Science 1981 214 : 24 30.
16. Hallett WH, Murphy WJ. Positive and negative regulation of natural killer cells: therapeutic implications. Semin Cancer Biol 2006 16 : 367 82.
17. Ortaldo JR, Winkler-Pickett RT, Nagashima K, Yagita H, Okumura K. Direct evidence for release of pore-forming protein during NK cellular lysis. J Leukoc Biol 1992 52 : 483 8.
18. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994 8 : 652 8.
19. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 2006 16 : 412 8.
20. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001 10 : 535 44.
21. Tam YK, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann HG. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 1999 10 : 1359 73.
22. Sun K, Wilkins DE, Anver MR et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005 106 : 3293 9.
23. Codony-Servat J, Tapia MA, Bosch M et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006 5 : 665 75.
24. Strehl B, Seifert U, Kruger E, Heink S, Kuckelkorn U, Kloetzel PM. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 2005 207 : 19 30.
25. Shi J, Tricot GJ, Garg TK et al. Bortezomib down-regulates the cell surface expression of HLA-class I and enhances natural killer cell-mediated lysis of myeloma. Blood 2007 111 : 1309 17.
26. Lundqvist A, Abrams SI, Schrump DS et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006 66 : 7317 25.
27. Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003 29 (Suppl. 1 41 8.
28. Marsoni S, Damia G. Molecular targeting: new therapeutic strategies to improve tumour apoptosis. Ann Oncol 2004 15 (Suppl. 4 iv229 31.
29. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001 61 : 3071 6.
30. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004 16 : 139 44.
31. Schumacher LY, Vo DD, Garban HJ et al. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 2006 176 : 4757 65.
32. Shi J, Tricot GJ, Garg TK et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 2008 111 : 1309 17.